The Supreme Court of Canada heard oral arguments on November 8, 2016 in an important appeal challenging the “promise of the patent” utility doctrine in Canada. In AstraZeneca Canada Inc. v. Apotex Inc. (Esomeprazole), the Supreme Court was asked to decide on the question of whether the doctrine properly exists in Canada. This article provides a brief summary of the oral arguments heard by the Supreme Court.